This report was first published by Endpoints News. To see the original version, click here
Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act.
Eli Lilly’s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the first time, CMS has also selected one additional drug for renegotiation: Boehringer Ingelheim’s diabetes drug Tradjenta. The negotiations will occur this year and take effect in 2028.
您已阅读13%（466字），剩余87%（3219字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。